UCLA stem cell researchers from the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research led by Dr. Amander Clark have developed the first biological resource that maps critical stages of human egg and sperm cell development during fetal life.
The resulting map has important implications for future research of infertility, such as for cancer survivors left unable to create eggs or sperm due to chemotherapy or radiation treatment. Another important result of this research is a better understanding of the cellular origins of testicular cancer, which is believed to begin in males during fetal life.
Stem Cell Research Provides Help for Breast Reconstruction
Irene MacKenzie had a lumpectomy for her early stage breast cancer leaving her with a hollow in her breast. The lumpectomy took care of the cancer, but what about her breast? Well, Irene was the first person in Britain to reap the benefits of Stem Cell […]
Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The
The metabolic state of glioma stem cells, which give rise to deadly glioblastomas, is significantly different from that of the brain cancer cells to which they give birth, a factor which helps those stem cells avoid treatment and cause recurrence later.
Researchers with the UCLA Department of Radiation Oncology at UCLA’s Jonsson Comprehensive Cancer Center also found for the first time that these glioma stem cells can change their metabolic state at will, from glycolysis, which uses glucose, to oxidative phosphorylation, which uses oxygen.
The glioma stem cells’ ability to change their metabolic state at will also allow these stem cells